Interim results of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in patients with NSCLC in a phase 1 trial.Elisa Fontana, Ramy Saleh, Nuria Kotecki et al.|Journal of Clinical Oncology|2025Cited by 2